IP Library Granted Patent US 12703686
Granted Patent B2
US 12703686 · App. 18/028,110 · Granted Aug 11, 2026

4-Methoxy-2-phenethyl isoindoline-1-one derivative and composition for treating neurological diseases, comprising same

Inventors: Jaekyung Jung (Cheongju-si, KR); Mi Kyeong Lee (Cheongju-si, KR); Dae Hee Lee (Cheongju-si, KR); Jae Kang Lee (Cheongju-si, KR); Sun Yeou Kim (Seoul, KR); Da Hye Yoon (Bucheon-si, KR); Seong Min Hong (Chungju-si, KR)
Assignees: CNG BIO CO., LTD.; CHUNGBUK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION; GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION
C07D209/44A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12703686
App. No.
18/028,110
Granted
Aug 11, 2026
Kind
B2
Abstract

The present invention relates to: a novel 4-methoxy-2-phenethyl isoindolin-1-one derivative compound having the ability to promote the increase of nerve growth factor, the ability to promote the growth of nerve cells, and antineuritic activity; and a composition for preventing, improving and treating neurological diseases, comprising the same.

Claims (23)

1 . A compound represented by Formula 9 below or a pharmaceutically acceptable salt thereof:

in the formula,

R 1 is hydrogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, or —N(Ra)(Rb);

R 2 , R 3 , R 4 , Ra and Rb are each independently hydrogen or alkyl; and

X is a single bond or a double bond.

2 . The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein

R 1 is hydrogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, hydroxyalkyl, alkoxyalkyl, or —N(Ra)(Rb);

Ra and Rb are each independently hydrogen or alkyl;

R 2 and R 4 are hydrogen;

R 3 is alkyl; and

X is a single bond or a double bond.

3 . The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein

R 1 is C 1 -C 6 alkyl, hydroxy, C 1 -C 6 hydroxyalkyl, or —N(Ra)(Rb);

Ra and Rb are each independently C 1 -C 6 alkyl;

R 2 and R 4 are hydrogen;

R 3 is C 1 -C 6 alkyl; and

X is a single bond or a double bond.

4 . A compound selected from the group consisting of compounds of the following formulas or a pharmaceutically acceptable salt thereof:

5 . A pharmaceutical composition for preventing or treating neurological diseases, comprising the compound represented by Formula 9 or the pharmaceutically acceptable salt thereof according to claim 1 .

6 . A food composition for preventing or improving neurological diseases, comprising the compound represented by Formula 9 or the pharmaceutically acceptable salt thereof according to claim 1 .

7 . A feed composition for preventing or improving neurological diseases, comprising the compound represented by Formula 9 or the pharmaceutically acceptable salt thereof according to claim 1 .

8 . A method for preventing or treating neurological diseases, the method comprising administering the compound represented by Formula 9 or the pharmaceutically acceptable salt thereof according to claim 1 to a subject in need thereof.

9 . A method for preventing or treating neurological diseases, the method comprising administering the compound or the pharmaceutically acceptable salt thereof according to claim 4 to a subject in need thereof.